130 related articles for article (PubMed ID: 7576948)
1. CD44 expression and modulation on human neuroblastoma tumours and cell lines.
Gross N; Beck D; Beretta C; Jackson D; Perruisseau G
Eur J Cancer; 1995; 31A(4):471-5. PubMed ID: 7576948
[TBL] [Abstract][Full Text] [Related]
2. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
[TBL] [Abstract][Full Text] [Related]
3. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
5. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC
Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
Combaret V; Gross N; Lasset C; Balmas K; Bouvier R; Frappaz D; Beretta-Brognara C; Philip T; Favrot MC; Coll JL
Br J Cancer; 1997; 75(8):1151-5. PubMed ID: 9099963
[TBL] [Abstract][Full Text] [Related]
8. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
9. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells.
Gross N; Balmas Bourloud K; Brognara CB
Exp Cell Res; 2000 Nov; 260(2):396-403. PubMed ID: 11035936
[TBL] [Abstract][Full Text] [Related]
10. Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells.
Gross N; Balmas K; Brognara CB
Cancer Res; 1997 Apr; 57(7):1387-93. PubMed ID: 9102228
[TBL] [Abstract][Full Text] [Related]
11. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
12. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation--sign of tumour cell revertance?
Ambros IM; Rumpler S; Luegmayr A; Hattinger CM; Strehl S; Kovar H; Gadner H; Ambros PF
Eur J Cancer; 1997 Oct; 33(12):2043-9. PubMed ID: 9516850
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
15. Analysis of candidate gene co-amplification with MYCN in neuroblastoma.
George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J
Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849
[TBL] [Abstract][Full Text] [Related]
16. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
[TBL] [Abstract][Full Text] [Related]
18. Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid.
David K; Ehrhardt A; Ollert MW; Erttmann R; Bredehorst R; Vogel CW
Eur J Cancer; 1997 Oct; 33(12):1937-41. PubMed ID: 9516828
[TBL] [Abstract][Full Text] [Related]
19. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
[TBL] [Abstract][Full Text] [Related]
20. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
Spengler BA; Lazarova DL; Ross RA; Biedler JL
Oncol Res; 1997; 9(9):467-76. PubMed ID: 9495452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]